Drugs that contain Fluticasone Furoate; Vilanterol Trifenatate

1. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(5 months from now)

US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

CN1585633A GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

CN103288793A GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

CN103288793B GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

CN101701006B GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

CN101701006A GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

CN1585633B GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

IN212714B GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(24 days ago)

IN200400346P2 GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(24 days ago)

EP2042168B1 GLAXO GRP LTD Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

EP2042168A1 GLAXO GRP LTD Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(24 days ago)

EP1425001B1 GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

EP1425001A1 GLAXO GRP LTD Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXO GRP LTD Medicament dispenser Jun, 2027

(4 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

US8161968 GLAXO GRP LTD Medicament dispenser Feb, 2028

(5 years from now)

US11116721 GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol Feb, 2029

(6 years from now)

US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser Oct, 2030

(8 years from now)

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.